Celsion Presents Combined Clinical Data from Two Phase I Trials
December 13, 2013 at 08:03 AM EST
Celsion Corporation (NASDAQ: CLSN ) today announced the presentation of the combined clinical study results from the Company's Phase I DIGNITY study and the Duke University sponsored Phase I trial of ThermoDox® plus hyperthermia in Breast Cancer Recurrences at the Chest Wall (BCRCW) at the 2013 San Antonio Breast